New major shareholder at Lysando
Until now the company founded in 2009 has been financed in the main by company founder Markus Matuschka von Greiffenclau who comes from nobility in Rheingau. For the first time a decision was made to get an independent shareholder into the same boat – from Thailand and not in the field of pharmacy. “We are able to out-licence our platform for the manufacture of antibiotic replacement substances with no hindrances from restriction licensing – ranging from disinfection to medicine”, emphasized Matuschka von Greiffenclau.
Lisando GmbH at BioPark Regensburg – the research subsidiary of Lysando AG, located in the Principality of Lichtenstein, specialises in lysis proteins – the artilysins. Using an in-house technology platform proteins are manufactured which can fight off gram-positive and gram-negative bacteria by making holes in the cell walls of microbes. This is particularly interesting in the fight against antibiotic resistant and persistent bacteria – for example in the development of new antibiotics. Boehringer Ingelheim is already one of Lysando’s customers. Now Regensburg wants to expand its presence in Asia. A laboratory in Bangkok has already been opened and the Thai Siam Cement Group (SCG) has secured 20% of the shares. The concern located in Bangkok is one of the largest Asian industry conglomerates whose focus lies in the field of cement manufacture and materials for the chemical and paper industry. It has not had much to do with biotechnology up to now. SCG-chief financial officer Chaovalit Ekabut hopes for a lot, “Artilysins offer an enormous potential with a view to their fields of application, demonstrating a close relationship with focus on application development at SCG, for example food stuff packaging, medical products and applications for household hygiene.“
For further information see: